BPC-157

What it is

BPC-157 is a synthetic pentadecapeptide (15 amino acids), also referred to as PL 14736 / PL-10; a brand name used outside the US is "Bepecin".S4 It is marketed for injury and tissue repair, but the rationale for those uses — tissue protection, angiogenesis, repair — remains preclinical.S3S4

Marketed as

Online sellers and clinics commonly market BPC-157 as a "healing" or "recovery" peptide — for tendon, ligament, muscle, and gut injuries and general tissue repair. These are marketing claims, not established effects; what the human evidence actually shows is below.S4

Regulatory status (US)

BPC-157 is not an FDA-approved drug, and it is not approved by any national regulatory authority for human use.S1S4 Under FDA's interim compounding policy it was placed in Category 2 — bulk substances that "may present significant safety risks" — and on the current FDA list (content current as of 2026-04-22) it appears in the "nominated but withdrawn" portion of Category 2.S1 BPC-157 (free base / acetate) is on the July 23, 2026 PCAC agenda for possible inclusion on the 503A Bulks List; the use FDA evaluated is ulcerative colitis (public docket FDA-2025-N-6895). Advisory-committee recommendations are non-binding, and the outcome is pending.S2

Around the world

BPC-157 is not approved for human use by any national regulator — not the FDA, the EU's EMA, the UK's MHRA, or Australia's TGA (which has denied compassionate-use requests).S4 Everywhere, it circulates as a research compound or gray-market product, not a licensed medicine.S1S4

Evidence

Human clinical evidence is limited. The first registered controlled trial is NCT07437547 ("BPC-HAMSTR") — a randomized, double-blind, placebo-controlled Phase 2 study in acute grade II hamstring strain (lead sponsor Hudson Biotech, estimated enrollment 120).S3 As of a 2026-06-30 re-check the study is still recruiting, with no results posted and estimated primary completion of February 2027.S3 Human benefit has not been established.S3S4

Anti-doping

On the WADA Prohibited List, BPC-157 is prohibited at all times under S0 (Non-Approved Substances) — the class for pharmacological substances with no current approval by any government regulatory authority for human therapeutic use.S4

Safety

Per the anti-doping authority, BPC-157's toxicity profile — short- and long-term — is unknown, and its use "may lead to serious negative health effects".S4 FDA separately notes insufficient safety information and potential immunogenicity for certain routes of administration.S1

What's changing

The July 23, 2026 PCAC discussion, and any FDA action after it, is the near-term event that could change BPC-157's compounding status; on the evidence side, results from NCT07437547 (expected around early 2027) would be the first controlled human data.S2S3